of Erika. XX data quarter Thanks, of but maternal we clinical Phase before first development our we In vaccine stage immunization the repeating. RSV. key bears the ever accomplished over ResVax We trial, recorded for by in said reported We've from In two X a after data programs. entire it this the late first this efficacy this year, trial efforts trials years industry.
and the accomplishments of teams. of clinical in nano-particle These in Additionally, vaccine vaccine. when earlier our the Novavax in the more and the development adult second selling broadly demonstrated value platform trials reflect importance a that differentiated are flu dedicated consecutive NanoFlu, flu for first time vaccine quarter, recombinant we market, to immunogenicity the best the remarkable the is compared older
our to have and good. ahead regulatory and talk which the with agencies, RSV future address both flu been about of we're doing very and So lying of rely programs, interactions challenges. The immediate on these let's us challenges what remain
from a the end and for document that Since announced preparing X now assembling been to Phase very the we In until better bring all an at large results poised X global immunogenicity, January, vaccine let's briefing a in have trial. cries talk a NanoFlu. to trial about X meeting. first, Phase of differentiated vaccine, So present market FDA we're Phase manufacturing of safety, our to data a we pivotal
immunogenicity trial meeting trial comparator, We expect of the market. that that that be getting clinical utilizes X trial could support an design get as upon light into green approval to the we vaccine license and effective pivotal cost against which seasonal pathway is outcome the Phase be a this X our agreed as will licensure. Phase our U.S. accelerated a If the future non-inferiority efficient the to conducting straightforward flu differentiated approach design
well all ResVax. our pathway timing current have as partners, waiting as to be provide focusing potential for that for surprise That investors, been licensure. It no are exactly on on. what us the and is we product to Turning should their clarity
attention month, of we infectious pediatric and breakthrough continue we important We summarized package, efficacy both licensure. data the Congress that Let have our an The good have news getting to we emphasize is meetings needed for the remain disease. last Phase we are me including can optimistic vaccine safety believe a at achieved world the and data globally. field X regulatory support that agencies of that
prepared provide these ResVax have briefing full with data our the available today. documents that containing submitted agencies We and picture
of a countries regulatory scientific States, options. now scheduled June with meetings clear We our four those the in out of expect additional other and and and advisors. have And agencies May national to in with meetings picture United come
discussions of that an report the very efforts in of Phase of X KOLs outcome RFP from data expect high have the We'll will a regulators world's the burden high Given the efficacy on we of the globally profile. with our with have trial infants the RSV globally first quarter. in disease vaccine, and combined will we third
Although, planning to we that my are we And have brief, do process. we would communications expect of this comments activities in all said the multiple been later regulatory have investor quarter.
the to financial Now, John a to I'll present overview. turn call over
